Compare IPWR & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPWR | COCH |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.1M | 49.7M |
| IPO Year | 2013 | N/A |
| Metric | IPWR | COCH |
|---|---|---|
| Price | $5.04 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.75 | $6.00 |
| AVG Volume (30 Days) | 479.5K | ★ 691.4K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,603.56 | $1.58 |
| Revenue Next Year | $1,800.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.62 | $0.36 |
| 52 Week High | $9.30 | $1.89 |
| Indicator | IPWR | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 60.24 |
| Support Level | $4.68 | $0.64 |
| Resistance Level | $5.54 | $0.90 |
| Average True Range (ATR) | 0.60 | 0.07 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 14.29 | 46.95 |
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.